We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Prostate Cancer Screening Improved by Repeating Abnormal Tests

By LabMedica International staff writers
Posted on 29 Dec 2015
For more than 20 years, the prostate-specific antigen (PSA) test has been used to help screen for prostate cancer, but in recent years, some task forces have called for this blood test to be abandoned because it leads to many unnecessary biopsies.

Prostate-specific antigen may be elevated because of prostate cancer or as a result of infection, physical activity, or sexual activity. More...
Variation in PSA concentrations can also be due to normal biological fluctuation or analytic and laboratory assay differences. As a result, PSA is sensitive but not specific for detecting prostate cancer, especially when levels are moderately elevated between 4 and 10 ng/mL.

Physicians and scientists at The Ottawa Hospital (ON, Canada) reviewed the medical records of 1,268 men who had an abnormal (high) PSA test result and were evaluated at the Ottawa Regional Cancer Assessment Centre between 2008 and 2013. In 25% of these men, the second PSA test came back normal. Only 28% of men with conflicting test results underwent a biopsy compared to 62% of men who had two abnormal test results, representing a 55% reduction in biopsies. In addition, only 3% of men with conflicting test results who had a biopsy were diagnosed with cancer within the year, compared to 19% of men who had two abnormal tests, suggesting that the second normal test is important. Repeated PSA test results were normal in 315 patients (24.8%).

Rodney H. Breau, MSc, MD, the senior author of the study said, “It is clear to me that any man with an abnormal PSA test should have this test repeated before a decision to biopsy. Some doctors and patients may be worried about missing a significant cancer diagnosis if they forgo a biopsy after conflicting test results, but our study shows this is very unlikely. It is also important to remember that the PSA test is just one factor we evaluate when deciding to do a biopsy, and these decisions are always made together with the patient, and can be revisited if risk factors change.” According to the Canadian Cancer Society, approximately 24,000 Canadians will be diagnosed with prostate cancer each year and the five-year survival rate is 96%. A PSA test costs approximately CAD 30, while a prostate biopsy costs approximately CAD 880.

The study was published on December 10, 2105, in the journal Mayo Clinic Proceedings.

Related Links:

The Ottawa Hospital



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researchers developed a blood test that accurately distinguishes early-stage breast cancer from healthy controls and may outperform tissue biopsy in predicting recurrence risk (Image Credit: Adobe Stock)

Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk

Breast cancer screening can reduce mortality, but early detection remains challenging when tumors are small or difficult to identify through imaging. Blood-based liquid biopsies offer a potential complementary... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.